Supra-papillary versus trans-papillary stenting for malignant biliary obstruction: an updated meta-analysis of randomized trials.
Scand J GastroenterolJun 30, 2026 (epub)
Clinical ResearchGastroenterology
Otavio Cosendey Martins, Vanio Antunes, Cynthia Florêncio de Mesquita et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis compared supra-papillary and trans-papillary stenting in 161 patients with malignant biliary obstruction. The study found that supra-papillary stenting significantly reduced stent occlusion rates (RR 0.76; 95% CI 0.59 to 0.97; p = 0.027) and increased stent patency duration (MD 65.29; 95% CI 4.87 to 125.71; p = 0.03).
Key findings
- Supra-papillary stenting reduced stent occlusion rates (RR 0.76; 95% CI 0.59 to 0.97; p = 0.027).
- Cumulative duration of stent patency was longer with supra-papillary stenting (MD 65.29; 95% CI 4.87 to 125.71; p = 0.03).
- No significant differences were found in stent migration (p = 0.473) or cholangitis occurrence (p = 0.519).
- Patient survival showed no significant difference (95% CI -1.64 to 179.38; p = 0.05).
Why it matters
The findings suggest that supra-papillary stenting may offer advantages in managing malignant biliary obstruction by reducing stent occlusion and prolonging stent patency, which could improve patient outcomes.